PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Michael Levy, MD, PhD - Test Your Knowledge: Are You Missing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease (MOGAD)?
Go online to PeerView.com/CTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) was identified as a distinct demyelinating disease entity only recently. Prior to this characterization of MOGAD, many patients were considered to have a variant of MS, NMOSD, or other neurologic condition. Now an international panel of experts has proposed diagnostic criteria that, when validated, promise to improve MOGAD diagnostic accuracy and confidence. This is particularly important, given that several clinical trials are investigating potential treatments for MOGAD. This unique PeerView activity will use problem-based educational interventions to expose learners to the science and clinical experience behind accurate diagnosis and best practices in management of MOGAD. You will be able to employ optimal clinical decision-making for your patients with MOGAD that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Explain the diagnostic criteria for MOGAD as proposed by the International MOGAD Panel; Employ recommended diagnostic tools (eg, the MOG antibody test, relevant MRI findings) to identify MOGAD and distinguish it from other demyelinating diseases; and Implement therapeutic strategies to provide acute treatment and relapse prevention in patients with MOGAD.